Sutro Biopharma, Inc., 111 Oyster Point, South San Francisco, CA 94080, USA.
Sutro Biopharma, Inc., 111 Oyster Point, South San Francisco, CA 94080, USA.
Curr Opin Biotechnol. 2022 Aug;76:102719. doi: 10.1016/j.copbio.2022.102719. Epub 2022 May 12.
Cell-free protein synthesis (CFPS) technologies have grown from lab-scale research tools to biopharmaceutical production at the Good Manufacturing Practice manufacturing scale. Multiple human clinical trials are in progress with CFPS-based products. In addition, applications of CFPS in research have continued to expand over the years and play an important role in biopharmaceutical product discovery and development. The unique, open nature of CFPS has enabled efficient non-natural amino acid (nnAA) incorporation into protein products, which expands the range of biotherapeutics that can be considered for novel treatments. The flexibility and speed of CFPS combined with novel nnAA capabilities are poised to open a new chapter in the continuing evolution of biotherapies.
无细胞蛋白质合成 (CFPS) 技术已经从实验室研究工具发展到符合良好生产规范 (GMP) 的生物制药生产规模。基于 CFPS 的产品有多个正在进行的人体临床试验。此外,CFPS 在研究中的应用多年来继续扩大,在生物制药产品发现和开发中发挥着重要作用。CFPS 的独特、开放性质使高效的非天然氨基酸 (nnAA) 掺入蛋白质产品成为可能,从而扩大了可用于新型治疗的生物治疗药物的范围。CFPS 的灵活性和速度与新型 nnAA 功能相结合,有望在生物疗法的持续发展中开辟一个新篇章。